Results 241 to 250 of about 151,900 (300)
Targeting Oncogenic KRAS Using Peptide Nucleic Acid Oligomers Attached to Cell-Penetrating Peptides. [PDF]
Int J Mol SciMondal J +13 more
europepmc +1 more source
Dietary-Derived Corchorus olitorius L. Extract Suppresses KRAS-Mutant Pancreatic Cancer by Activating Ferritinophagy-Dependent Ferroptosis. [PDF]
J Food SciTseng CY +6 more
europepmc +1 more source
Daraxonrasib and Beyond: Pan-RAS Inhibition, Resistance, and Next-Generation Strategies. [PDF]
Cancer SciHonda R.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Current Opinion in Chemical Biology, 2021
The protein KRAS has for decades been considered a holy grail of cancer drug discovery. For most of that time, it has also been considered undruggable. Since 2018, five compounds have entered the clinic targeting a single mutant form of KRAS, G12C. Here, we review each of these compounds along with additional approaches to targeting this and other ...
Daniel A, Erlanson, Kevin R, Webster
openaire +2 more sources
The protein KRAS has for decades been considered a holy grail of cancer drug discovery. For most of that time, it has also been considered undruggable. Since 2018, five compounds have entered the clinic targeting a single mutant form of KRAS, G12C. Here, we review each of these compounds along with additional approaches to targeting this and other ...
Daniel A, Erlanson, Kevin R, Webster
openaire +2 more sources
European Journal of Cancer, 2009
The anti-epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab have been demonstrated to be efficient in the treatment of irinotecan-resistant and chemorefractory metastatic colorectal cancer (mCRC) respectively. However, these costly and potentially toxic treatments are only efficient in a small proportion of patients.
Pierre, Laurent-Puig +2 more
openaire +2 more sources
The anti-epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab have been demonstrated to be efficient in the treatment of irinotecan-resistant and chemorefractory metastatic colorectal cancer (mCRC) respectively. However, these costly and potentially toxic treatments are only efficient in a small proportion of patients.
Pierre, Laurent-Puig +2 more
openaire +2 more sources